: Safety and Efficacy of abbreviated (12 hr) Magnesium Sulfate (MgSO4) therapy) vs. traditional 24 hrs therapy after delivery in Severe Preeclampsia: a Randomized Clinical Trial

DirectorPGIMER Chandigarh0 个研究点目标入组 240 人开始时间: 待定最近更新: 2021年11月24日

研究概览

暂无简介。

•Inclusion Criteria
•1.Women with severe-preeclampsia, diagnosed during ante partum, intrapartum, or postpartum, are eligible for inclusion after delivery.
•A diagnostic criterion for severe preeclampsia includes:
•sustained systolic blood pressure of >=160 mm Hg;
•sustained diastolic blood pressure of >=110 mm Hg;
•proteinuria >3 + on dipstick or >=5 g/24- hour urine collection;
•oliguria (urine output <500 mL in 24 hours );
•the presence of persistent headache, visual disturbances, or epigastric or right upper quadrant pain; thrombocytopenia ; impaired liver function; pulmonary edema or cyanosis;
•fetal growth retardation;
•or superimposed severe pre-eclampsia with pre-existing chronic hypertension.
•2.Agree to comply with study procedures;
•3. > 18 years of age;
•4.Give informed consent for study participation

•Exclusion Criteria
•Associated maternal diseases;
•Use of illicit drugs or other medications that might interfere with maternal hemodynamics;
•Contraindications to the use of magnesium sulfate: drug hypersensitivity, oliguria with urine output below 25ml/h; anuria (absent urine output), myasthenia gravis.
•Comatosed patients
•Pulmonary oedema
•Patients who have received MgSO4, Phenytoin, Diazepam before coming to hospital
•Intra cranial bleeding

发起方

DirectorPGIMER Chandigarh